Inflammatory Bowel Disease
Conditions
Brief summary
This is a prospective, controlled and observational study. Participants underwent a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 meters above sea level (m.a.s.l.) in a hypobaric pressure chamber. Clinical parameters, as well as blood and stool samples and biopsies from the sigmoid colon (by sigmoidoscopy) are collected at subsequent time points. The investigators goal is to evaluate if a 3-hour stay at high altitude (4, 000 m) can alter disease activity and can modulate a pro inflammatory reaction.
Detailed description
To evaluate the potential influence of hypoxia on the course of IBD on a biomolecular level, and to test the effects of hypoxia under standardized conditions, the investigators initiated a prospective and controlled investigation in healthy controls and IBD patients in stable remission. the investigators primary aim is to show that a 3-hour stay at high altitude can alter disease activity of IBD. Ten healthy volunteers, 11 Crohn's disease (CD) patients and 9 ulcerative colitis (UC) patients underwent a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l. in a hypobaric low-pressure chamber situated at the Swiss Aeromedical Center, Dubendorf, Switzerland. Stool samples for the analysis of calprotectin and microbiotal composition, biopsy samples from the rectosigmoid region, and blood samples were repetitively collected and analysed in conjunction with detailed records of clinical symptoms over a subsequent interval of 4 weeks.
Interventions
OTHERhypobaric pressure chamber
hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control
OTHERSigmoidoscopy
To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H&E).
Sponsors
Triemli Hospital
Zurich Center for Integrative Human Physiology
Institute of Biostatistics
Insel Gruppe AG, University Hospital Bern
Institute of Physiology Irchel
Institute of Veterinary Physiology
Swiss Aeromedical Center Switzerland
Institute of Experimental Immunology
University Hospital, Zürich
University of Zurich
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* had a diagnosis of Crohn's disease or ulcerative colitis at least 6 months prior to inclusion * gave written consent * were in clinical remission (measured by Harvey Bradshaw Activity Index (HBI) in CD and the partial Mayo Score for UC)
Exclusion criteria
* had contraindications for a sigmoidoscopy * had intercurrent bacterial or viral intestinal disease (by culture or serology) * were pregnant or breast feeding * had a severe concomitant disease which excluded from participating in the study by means of the study physician * were likely to or showed no cooperation for the study procedures * had active infection or systemic antibiotic, antiviral or antifungal treatment 3 weeks before baseline * were suffering from short-bowel syndrome * were receiving parenteral nutrition * had a clinical condition which did not allow a stay at heights of 4,000 m.a.s.l. * were claustrophobic
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of Harvey Bradshaw Activity Index (HBI) | 4 weeks | Harvey Bradshaw Activity Index (HBI) in Crohn's disease (CD): To calculate the clinical activity of patients with CD the Harvey Bradshaw Activity Index (HBI) was used. This index includes general wellbeing, abdominal pain, the number of bowel movements, abdominal resistance and CD associated extraintestinal diseases. Each category has a point value assigned and from the sum of all categories a point value is calculated. |
| Change of partial Mayo Score | 4 weeks | partial Mayo Score for Ulcerative Colitis (UC): To calculate the clinical activity of patients with UC the partial Mayo Score was used. This clinical index includes the stool frequency, the amount of blood in the stool and the physician rating of disease activity. Each category has a point value assigned from 0 to 3 and from the sum of all categories a point value was calculated. Remission is defined as 0-1 points, mild disease 2-4 points, moderate disease 5-6 points and severe disease as 7-9 points. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in levels of angiotensin and vasopressin in urine | 4 weeks | — |
| Change in levels of catecholamines (adrenaline and noradrenaline) in blood | 4 weeks | — |
| change in levels of hypoxia-inducible factor (HIF)-1 | 4 weeks | — |
| Inflammation in sigmoid colon | 4 weeks | Assessed by sigmoidoscopy: signs of inflammation: * decreased vascular pattern * ulcers * bleeding |
| Change in pro- and anti-inflammatory cytokins | 4 weeks | tumor necrosis factor alpha (TNF-α), tumor necrosis factor (TNF), interleukin-1β (IL-1β), interferon-gamma (IFNg), interleukin-10 (IL-10) |
| Change in bladder volume | 4 weeks | measured by sonography (ml) |
Outcome results
None listed